Europe and Asia/Pacific to widely differ in future obesity

While it is universally true that the incidence and prevalence of obesity is increasing steadily, it is not nearly as true that the rate of growth is consistent globally and differences in these rates are compounded by differences in the market impact they have for the adoption and growth in the use of obesity treatment products.  Differences in demographics, socioeconomic trends, regulatory environments and other forces result in some starkly different pictures of obesity markets from region to region.

As an example, below are illustrated the distribution of obesity markets (figures in $ millions) by treatment type for Asia/Pacific versus Europe for both 2011 and 2019.  The economic growth of Asia/Pacific markets, particularly China and an associated growth in incidence/prevalence in obesity there will translate into a larger aggregate market for obesity treatments in 2019 for Asia/Pacific than in Europe, reversing the current picture in 2011.

Source: Report #S835, "Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019."

A $10 billion global medtech market for ablation technologies

The world market for energy-based ablation devices includes electrical, radiation, light, radiofrequency, ultrasound, cryotherapy, thermal, microwave and hydromechanical. 

The total market in 2009 was valued at nearly $10 billion. For the market period 2010-2019, the compound annual growth rate (CAGR) for the global market is projected to be 11.2%. The CAGR is deceptively modest, because these figures reflect the combined market sizes and growth rates of nine sectors. Those nine sectors, or modalities, vary widely in growth rates: from thermal, with an estimated CAGR (’09-’19) of under 3%, to cryotherapy with a CAGR of 19.5%. The energy-based ablation devices market is growing vigorously and will continue to grow at a strong rate during the study period.

(As defined in the MedMarket Diligence report #A145), the Americas consist of the USA, Canada, Mexico and Brazil; the European Union (EU) includes the United Kingdom, Germany, France, Spain, Italy and BeNeLux; Asia-Pacific represents Japan, China, India and Australia.

The different energy-based ablation segments vary widely in size, as shown in the following exhibit. Radiation accounted for one-third of the entire market in 2009, followed by light-based ablation (e.g., laser) with 19%. These two modalities accounted for 52% of the dollar value of the energy-based ablation device market in 2009. The CAGR (’10-’19) for radiation is about 8.1%; that of light is about 11%. 

Global Ablation Market Segments

Source: MedMarket Diligence, LLC, Report #A145, "Ablation Technologies Worldwide Market, 2009-2019: Products, Technologies, Markets, Companies and Opportunities".

Global diabetes market growth by segment, regions

The global market for products in the management of diabetes currently stands at $41 billion and is on pace to grow to over $114 billion by 2018.  Products include glucose meters, lancets, test strips, continuous blood glucose meters, insulin, insulin pumps, syringes and other insulin delivery devices and anti-diabetic drugs.  The bulk of product revenues come from three segments — test strips, insulin and anti-diabetic drugs — which will remain the largest sources of product revenues over the next ten years.  The most significant growth, however, will come from the nascent segment of continuous blood glucose monitors, which provide significantly added clinical benefit at only a modestly higher cost compared to standard blood glucose meters.

The growth in global market for diabetes products from 2010 to 2018 is illustrated by product segment below:

Source: MedMarket Diligence, LLC; Report #D510, "Diabetes Management: Products, Technologies, Markets and Opportunities Worldwide 2009-2018."

 

Currently, the U.S. remains the single largest source of product revenues in diabetes management, at roughly 37% of the global market, but that percentage will drop to 28% by 2018, primarily as a result of significant growth in Asia/Pacific, which is due in no small measure to the rapid economic development of China, which demonstrate growth in both pricing and expansion of healthcare coverage to its 23 million diabetics.

The growth in the global market for diabetes products from 2010 to 2018 is illustrated by major geographic area below:

Source: MedMarket Diligence, LLC; Report #D510.

Clinical Management of Obesity Worldwide

Publishing in November 2010:

Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2009-2019

– 300 pages  – 95 Exhibits  – 54 Company Profiles  – February 2011  – Report #S835

Order online or via order form.
(Save $1,000 with advance price discount)

[This report description and table of contents is also available at report S835.]

This report is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity (bariatrics). The report describes the current and projected patient population in obesity, detailing their incidence worldwide, with available incidence by country for the U.S., major European countries, major countries in Asia/Pacific (including Japan, China, India and Australia), the clinical practices in their management to encompass surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The report describes clinical trends in the management of the obese. The report details the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy and other therapies under development, and will provide current and worldwide market forecasts (2009-2019) separately for pharmaceuticals (with separate segment forecast data for satiety, malabsorption, appetite suppression and combination drugs) and devices (with separate segment forecast data for stomach restriction artificial fullness, malabsorption, gastric emptying and appetite suppression), with current (2009) market shares of the leading competitors in each segment. The report profiles 60 of the leading competitors, detailing current and potential position in the market, their products and their market strengths and likelihood of future success.

Preliminary Table of Contents

EXECUTIVE SUMMARY

SECTION 1: CLINICAL BACKGROUND OF OBESITY
1.1 Clinical Diagnosis of Obesity
1.1.1 Body Mass Index Scale
1.1.2 Measuring BMI vs. Measuring Adiposity
1.1.3 Classification of Obesity
1.1.4 Overweight, Obesity, Morbid Obesity, Super Obesity
1.1.5 Genetic Testing for Obesity
1.2 Obesogenic Influences
1.2.1 Dietary Changes Over the Last Twenty Years
1.2.2 Sedentary Lifestyles
1.2.3 Ongoing Research into Causes
1.3 Metabolic Pathways of Energy Homeostasis
1.3.1 Role of the Hypothalamus
1.3.2 Role of the Stomach
1.3.3 Role of the Small Intestine
1.3.4 Role of the Pancreas
1.3.5 Role of Adipose Tissue, An Endocrine Organ
1.3.6 Other Peptides
1.3.7 Obesity as Survival Mechanism
1.4 Co-Morbidities of Overweight and Obesity
1.4.1 Metabolic Syndrome
1.4.2 Effects of Obesity on Immune Function
1.4.3 Racial Differences in Co-morbidities
1.4.4 Type 2 Diabetes and Insulin Resistance
1.4.5 Hypertension
1.4.6 Dyslipidemia
1.4.7 Depression
1.4.8 Osteoarthritis
1.4.9 Asthma
1.4.10 Sleep apnea
1.4.11 Obesity and Cancer
1.5 Global Incidence and Prevalence of Obesity
1.5.1 By Geographic Region
1.5.1.1 USA, Canada, Mexico, Brazil
1.5.1.2 European Union
1.5.1.3 Asia-Pacific
1.5.2 By Age Group
1.5.2.1 Incidence and Prevalence among Children
1.5.2.2 Incidence and Prevalence among Elderly
1.5.3 Incidence and Prevalence of Morbid Obesity
SECTION 2: THE IMPACT OF OBESITY
2.1 Costs Related to Treating Obesity and Co-Morbidities
2.1.1 Current Healthcare Expenses
2.1.2 Breaking the Bank: Predictions of Future Healthcare Expenses
2.1.3 Healthcare Reform and Obesity
2.2 Impact on Businesses
2.2.1 Increased Health Insurance Costs
2.2.2 Increase in Workers’ Compensation Costs
2.2.3 Debate: Pay Employees to Lose Weight?
2.3 Legislating Prevention and Weight Loss
2.3.1 Changing Society: Educating Children as well as Adults
2.3.2 Pressure on the Food Industry
SECTION 3: CLINICAL APPROACHES TO THE TREATMENT OF OVERWEIGHT AND OBESITY
3.1 Role of Behavior Modification and Lifestyle Changes
3.1.1 Behavior Modification Programs: Decidedly Mixed Success
3.1.2 Medically Supervised Low Calorie and Very Low Calorie Diets (LCDs and VLCDs)
3.1.3 Why Diets Usually Fail
3.2 Pharmaceutical Treatment of Obesity: Past, Present and Future Drugs
3.2.1 The Bloom is Off the Rose: Promising Drugs Which Have Failed, and Why
3.2.2 Drugs Currently on the Market
3.2.2.1 Appetite Suppression Drugs
3.2.2.2 Malabsorption Drugs
3.2.2.3 Satiety Drugs
3.2.2.4 Combination Drugs
3.2.3 Areas of Pharmaceutical Research
3.2.3.1 Melanocortin Receptor System
3.2.4 Drugs in the Pipeline—But Will They Hold Up?
3.2.4.1 Appetite Suppression Drugs
3.2.4.2 Malabsorption Drugs
3.2.4.3 Satiety Drugs
3.2.4.4 Combination Drugs
3.2.5 Safety: The Major Diet Drug Hurdle
3.2.6 After ‘Phen-Fen’ Experience, Will Physicians Prescribe Off-Label Combinations?
3.3 Non- Pharmaceutical Options for Treating Obesity
3.3.1 Permanent Surgical Modification
3.3.2 Surgical Revision of Bariatric Procedures
3.3.3 Short-Term Surgical/Device Solutions
3.3.4 Invasive Devices to Treat Obesity
3.3.4.1 Devices to Restrict Stomach Volume
3.3.4.2 Artificial Fullness Devices
3.3.4.3 Malabsorption Devices
3.3.4.4 Devices to Control Gastric Emptying
3.3.4.5 Appetite Suppressive Devices
SECTION 4: MARKET ASSESSMENT
4.1 Global Market for the Treatment of Obesity
4.1.1 Pharmaceuticals
4.1.1.1 Satiety
4.1.1.2 Malabsorption
4.1.1.3 Appetite Suppression
4.1.1.4 Combination Drugs
4.1.2 Devices
4.1.2.1 Stomach Restriction
4.1.2.2 Artificial Fullness
4.1.2.3 Malabsorption
4.1.2.4 Gastric Emptying
4.1.2.5 Appetite Suppression
4.2 Market Shares of Leading Companies
4.2.1 Leading Pharmaceutical Companies
4.2.2 Leading Device Companies
4.3 Americas Market for the Treatment of Obesity
4.3.1 USA
4.3.2 Canada
4.3.3 Mexico
4.3.4 Brazil
4.4 European Market for the Treatment of Obesity
4.4.1 United Kingdom
4.4.2 France
4.4.3 Germany
4.4.4 Italy
4.4.5 Spain
4.4.6 Rest of Europe
4.5 Asia-Pacific Markets for the Treatment of Obesity
4.5.1 Japan
4.5.2 India
4.5.3 China
4.5.4 Australia
4.5.5 Russia
4.6 ROW Markets for the Treatment of Obesity
4.7 Market Drivers and Restraints
4.7.1 Drivers
4.7.2 Restraints
4.8 Marketing Opportunities
SECTION 5: COMPANY PROFILES
5.1 Abbott Laboratories
5.2 Allergan
5.3 Amylin Pharmaceuticals
5.4 Arena Pharmaceuticals
5.5 AstraZeneca
5.6 BAROnova Therapeutics
5.7 BaroSense
5.8 Covidien
5.9 CR Bard, Inc.
5.10 Eli Lilly & Company
5.11 EndoGastric Solutions
5.12 EndoSphere
5.13 EndoVx
5.14 EnteroMedics
5.15 Ethicon Endo-Surgery (JNJ)
5.16 Gelesis, Inc.
5.17 GI Dynamics
5.18 GlaxoSmithKline
5.19 Helioscopie
5.20 Interleukin Genetics
5.21 IntraPace
5.22 Merck
5.23 Nestlé Healthcare Nutrition
5.24 NeuroSearch A/S
5.25 Novo Nordisk
5.26 Orexigen
5.27 Pfizer
5.28 ReShape Medical
5.29 Rhythm Pharmaceuticals
5.30 SafeStitch Medical, Inc.
5.31 Sanofi Aventis
5.32 Satiety
5.33 Scientific Intake, LLC
5.34 Silhouette Medical, Inc.
5.35 Spatz FGIA, Inc.
5.36 USGI Medical
5.37 ValenTx, Inc.
5.38 Verva Pharmaceuticals Ltd.
5.39 Vivus, Inc.
APPENDIX I: CLINICAL TRIALS
APPENDIX II: APPENDIX
Company Contact Details
Terms and Abbreviations Used in this Report

Surgical Sealants, Glues, Hemostasis, and Other Wound Closure Well Established Yet Still Growing Strong, According to New MedMarket Diligence Report

With its products filling many niches, established companies making acquisitions, startups still entering the market and clinical practice steadily adopting products in existing and new uses, the sealants, glues and related products markets reflect the characteristics of both well established and emerging technologies. A new report from MedMarket Diligence details the status and outlook for the products, technologies, companies and global markets.

Foothill Ranch, CA (PRWEB) October 28, 2010 — According to the newly released report, “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2008-2015”, from MedMarket Diligence, the market for surgical closure and securement has entered a phase in which major driving forces are the introduction of new procedures and techniques by the surgical profession, the development by the medical device industry of new wound closure devices and biomaterials, and the growing willingness of surgical specialists to use these devices in appropriate circumstances. There is now a continuum between simple closure using sutures and the use of specially designed devices and delivery systems with new bioresorbable securement materials either as supplements to conventional closure methodology or as stand-alone replacements.

“There is a broad spectrum of activity in the ‘advanced wound closure’ or ‘securement’ market, with the characteristics of disruptive innovation of new technologies all the way through market consolidation and price erosion,” says Patrick Driscoll of MedMarket DIligence. “Surgical sealants, glues and related products are to some degree routine in clinical practice and to some degree still seeking to prove their utility in new applications, while traditional sutures, staples, clips, tapes and other products are struggling to maintain their competitiveness.”

Globally, the market has reached $10 billion for surgical sealants, glues, hemostasis, sutures, staples/clips, tapes and anti-adhesion products, with annual sales growth among the constituent segments ranging from 2.6% to in excess of 14% annually. The market continues to be characterized by the introduction of many new products, formation of new companies, growth of existing applications, and adoption of new applications. Simultaneously the market is evolving through consolidation and other dynamics typical of established markets.

The MedMarket Diligence report #S180, “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2008-2015”, details the complete range of sealants & glues technologies used in traumatic, surgical and other wound closure, from tapes, sutures and staples to hemostats, fibrin sealants/glues and medical adhesives. The report details current clinical and technology developments in this huge and rapidly growing worldwide market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity.

This report is a market and technology assessment and forecast of surgical sealants, glues, hemostasis, other wound closure and anti-adhesion. The report details the current and emerging products, technologies and markets involved in wound closure and sealing using sutures and staples, tapes, hemostats, fibrin and sealant products, medical adhesives and products to prevent surgical adhesions. The report provides a worldwide historic (from 2008), current and annual forecast to 2015 of the markets for these technologies, with particular emphasis on the market impact of new technologies through the coming decade. The report provides specific forecasts and shares of the worldwide market by segment for the U.S., Europe (United Kingdom, German, France, Italy, BeNeLux), Latin America, Japan, Korea and Rest of World.

The report provides background data on the surgical, disease and traumatic wound patient populations targeted by current technologies and those under development, and the current clinical practices in the management of these patients, including the dynamics among the various clinical specialties or subspecialties vying for patient population and facilitating or limiting the growth of technologies.

The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a five-year forecast. The report also assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

The MedMarket Diligence report, “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2008-2015,” is described in detail, with a complete table of contents and list of exhibits at http://mediligence.com/rpt/rpt-s180.htm.

The report may be purchased for immediate download from http://mediligence.com/store/page41.html or may be purchased via order form at http://mediligence.com/order_forms/s180_order.pdf.

MedMarket Diligence provides data and insight to the medical products, investment and other industries on advanced medical technologies through focused medical technology market and assessment Reports and the Medtech Startups Database.

Surgical securement market, Latin America

The securement market, encompassing fibrin sealants/glues, high strength glues (cyanoacrylates, others), hemostatic agents, sutures, staples, other mechanical closure and products for the prevention of post-surgical adhesion, in most segments reflects an advanced wound technologies market.  As is the cast with virtually all medtech markets, the dominant geographies driving securement revenues are the U.S., Europe and Asian countries like Japan and Korea.  However, considerable attention is being given to Latin America, based on the level of healthcare market development, the population and potential caseload, and the relative ease of distribution, particularly for U.S.-based manufacturers (although, not to overstate the opportunity, since by comparison to the well established western markets, Latin America is clearly less driven by high healthcare expenditure and utilization of advanced technologies).

By capitalizing on existing distribution networks, trade agreements and the simple proximity of geography for major U.S. manufacturers, the opportunity of Latin America has been a profitable consideration.

Source: MedMarket Diligence, LLC; report #S180.

The growing need for diabetes management globally

Population growth, trends in obesity prevalence, economic drivers and other forces are creating an enormous need for products in the management of diabetes.  In the aggregate, over the next twenty years, the prevalence of diabetes in the adult population (age 20-79) will increase from 285 million worldwide in 2010 to 438 million in 2030, an overall increase of 54%.

NAC: North America and Caribbean region; MENA: Middle East and North Africa region; SEA: South East Asia region; EUR: European region; SACA: South and Central America region; WP: Western Pacific region; AFR: Africa region.

Source: IDF Diabetes Atlas and MedMarket Diligence, LLC.

 

The greatest number of newly diagnosed diabetes mellitus patients are arising in South East Asia (SEA), Western Pacific (WP) and Middle East and North Africa (MENA), as illustrated below (figures in millions):

Source: IDF Diabetes Atlas and MedMarket Diligence, LLC.

 

Growth of the diabetes patient population in North America and Europe, with its well developed economies and healthcare system infrastructure, is occurring at a compound annual growth rate, from 2010 to 2030, of 1.8% in North America and 0.9% in Europe. These new patients will be readily integrated into the existing infrastructure of clinical management.  By contrast, however, the large numbers of patients arising from South East Asia, the Western Pacific and the Middle East and North Africa will demand development of infrastructure to manage these patients and supply the appropriate diagnostic and therapeutic products for management of their diabetes mellitus.


Data is drawn from the International Diabetes Federation and MedMarket Diligence Report #D510, "Worldwide Diabetes Management."

U.S. and Asia/Pacific diabetes markets differentiated

Due to a variety of factors in the manifestation and treatment of diabetes in different geographies, driven by  differences in incidence, associated pathologies, clinical practice patterns, local reimbursement rates, etc., the distribution of the sales in diabetes for different product types varies from one geography to the next.  However, the most significant distinction in comparing markets is aggregate size.  Below is illustrated the distribution of diabetes product sales ($millions) by type for the U.S. and for Asia/Pacific.  At the outset, the U.S. market, as with most medtech markets, dominates due to population (healthcare spending per capita GNP).  

 

But when viewed on a percentage of total market, the two markets, for all their geographic, cultural and other differences, are not remarkably different.

Source: MedMarket Diligence, LLC; Report #D510, "Worldwide Diabetes Management Market."

Sealants, glues, wound closure, anti-adhesion market segments by country

The global market for surgical sealants, glues, other wound closure and anti-adhesion products (collectively referred to as "securement "products) is, like many medtech markets, dominated by the U.S., followed by Europe.  But as one examines the performance of individual product segments in this market, it becomes clear that local markets have enough differences in their drivers to result in surprising variation from one another.

Below are illustrated the absolute size of the markets for products in securement by country and the relative contribution of revenues from each securement product type by country.  The differences stand out.

Source: Preliminary findings, Report #S180, "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2010-2015". (Publishing October 2010)

Continuous blood glucose monitors in diabetes

Continuous blood glucose monitors (CBGMs), which regularly report blood glucose levels and, more importantly, provide alarms for when levels approach critical highs and lows and, even further, advance warning of the trend toward such levels, are a major new area of market opportunity for technologies in diabetes.  On their own, they offer the ability to provide advance intervention for diabetics whose blood glucose is poised to drop to rise to unhealthy levels.  Further, their use in providing patients and their clinicians with data on patterns of blood glucose response to carbohydrate intake, insulin infusion, exercise and other important variables can move diabetics' care toward normalizing glucose levels and avoid the complications of hypo- and hyperglycemia.

Combined in in initially open loop and, eventually, closed loop systems integrated with insulin pumps and CBGMs, these systems represent the potential "artificial pancreas" that is a long sought-after goal in diabetes management.  The only remaining constraints (since open loop systems are already available) is the necessary algorithms and their FDA approval in an integrated device that does not require user input to relate glucose levels to insulin dosage.

The market potential for CBGMs varies by geography according to different local  adoption rates and other variables.  See below for relative growth rates for the market in CBGMs:

Source: MedMarket Diligence, LLC; Report #D510, "Diabetes Management: Products, Technologies, Markets and Opportunities Worldwide 2009-2018."